Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Cancers

NCT03054298 is registered in ClinicalTrials.gov with University of Pennsylvania as lead sponsor.

NCT NCT03054298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03054298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Cancers
Lead sponsor
University of Pennsylvania
Phase
Phase 1
Overall status
Completed
Start date
April 6, 2017
Completion date
July 30, 2024
Enrollment
65 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube cancer, lung adenocarcinoma, mesothelioma peritoneum, mesotheliomas pleural, ovarian cancer, peritoneal carcinoma